ReviewDrug design, development and therapy2025
Acute Kidney Injury Associated with the Concomitant Use of Vancomycin and Piperacillin-Tazobactam.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between concomitant use of vancomycin-piperacillin/tazobactam and acute kidney injury in real-world setting.Frontiers in physiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the increased use of vancomycin (VAN) in combination with piperacillin-tazobactam (TZP) has raised significant concerns in clinical practice regarding the heightened risk of acute kidney injury (AKI). This topic has become a focal point in clinical therapeutics due to the widespread application of VAN alongside TZP. The specific mechanisms underlying vancomycin and piperacillin-tazobactam (VPT) associated AKI remain unclear. In this review, we discuss several controversial or underexplored aspects of current research. While the majority of literature links VPT to an elevated risk of AKI, numerous studies present conflicting outcomes. Mechanisms proposed for the increased risk of AKI associated with VPT, based on clinical observations and animal studies, include additive toxic effects, increased VAN exposure due to concomitant use with TZP, exacerbated VAN-induced oxidative stress injury in proximal renal tubule by TZP, pseudo-nephrotoxicity mediated by VPT-induced impaired creatinine secretion, or a combination of the aforementioned mechanisms. Additionally, this review outlines potential strategies that might effectively mitigate the risk of VPT-induced AKI, offering insights and future implications in the realm of pharmacovigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.